Tissue Plasminogen Activator Induces Pancreatic Cancer Cell Proliferation by a Non-Catalytic Mechanism That Requires Extracellular Signal-Regulated Kinase 1/2 Activation through Epidermal Growth Factor Receptor and Annexin A2

This publication has 75 references indexed in Scilit:

• Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer
  British Journal of Cancer, 2006
• Tenascin C and annexin II expression in the process of pancreatic carcinogenesis
  The Journal of Pathology, 2006
• Epidermal growth factor receptor (EGFR) signaling in cancer
  Gene, 2005
• KLF11 mediates a critical mechanism in TGF-β signaling that is inactivated by Erk-MAPK in pancreatic cancer cells
  Gastroenterology, 2004
• Binding of Urokinase-type Plasminogen Activator to Its Receptor in MCF-7 Cells Activates Extracellular Signal-regulated Kinase 1 and 2 Which Is Required for Increased Cellular Motility
  Published by Elsevier ,1998
• The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro
  Oncogene, 1998
• Isolation of tissue‐type plasminogen activator, cathepsin H, and non‐specific cross‐reacting antigen from SK‐PC‐1 pancreas cancer cells using subtractive hybridization
  FEBS Letters, 1996
• Annexin II tetramer: structure and function
  Molecular and Cellular Biochemistry, 1995
• Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha.
  Journal of Clinical Investigation, 1992
• The epidermal growth factor receptor in human pancreatic cancer
  The Journal of Pathology, 1992